However, it is difficult for doctors to determine which patients are not responding to the drugs early in the process, so alternative treatment options can be tried. As a result, patients can be over-treated, and unnecessarily suffer the side-effects of chemotherapy before realizing it is having little effect.
Masters student Xiaohui Wang at the Department of Computational Mathematics at the University of Waterloo set out to change this through a Mitacs-Accelerate internship with Ontario-based Rna Diagnostics.
However, the cost of research and development of natural health products is often impossibly steep as the products must be rigorously tested and proven before they can be placed on store shelves.
With this challenge ahead of them, the Alberta “phyto-pharmaceutical” biotech company, SinoVeda, turned to Mitacs-Accelerate to assist in the advanced testing of its latest natural calcium supplement which is currently undergoing clinical trials.
The company is developing a novel cancer vaccine based on a specific antigen and needed the research expertise to help them understand, at a molecular level, how that antigen is expressed in different types of cancer. They turned to Dalhousie postdoctoral fellow Olga Hrytsenko for insight. Olga’s 17 years of molecular biology experience is the “perfect fit” for the project says Marianne Stanford, Director of Research, at Immunovaccine.
The research led to a 78% reduction in CT image noise which facilitates a corresponding decrease in the patient radiation exposure required for high quality CT images, saving patients from the potentially harmful effects of X-ray dose radiation. Below is an exclusive interview with Mr. Hashemi, who won the Mitacs Award for Novelty in Application, as presented by the Honourable Gail Shea, Minister of National Revenue at the 2nd Annual Mitacs Awards Reception, held November 28th in Ottawa.
Because of this research, BC Children’s Hospital can how examine all new cases of pediatric brain tumors throughout the entirety of Western Canada with precision and accuracy – thus reducing the (often excessive) intensity of treatment for children with cancer while still effectively treating the disease. Below is an exclusive interview with Ms.
The research led to the completion of a motorized incubator device that now enables researchers to observe live cells for days at a time as they are stretched under the microscope. His work may help to cure a devastating skin blistering disease called epidermolysis bullosa simplex. Below is an exclusive interview with Mr.
By 2020, it is estimated that diabetes will cost the Canadian healthcare system $16.9 billion a year. In response, Calgary-based Orpyx Medical Technologies is developing a product that is garnering the attention of the diabetes technology community. The SurroSense Rx is a pressure sensitive insole that relays plantar pressure information to a wristwatch, notifying the user when damage is being done to their feet so that behavior can be modified to avoid complications.
The well-informed and critical nature of this response which contributed to the downfall of the Kony campaign is part of a growing trend among would-be philanthropists to scrutinize the practices of charities to whom they might otherwise give. Recognizing such a trend in philanthropy, Calgary-based Dexterity Ventures Inc. saw a need to match donors to deserving charities, launching Place2Give.com as a depository of accessible and transparent information for over 86,000 registered Canadian charities.
Every year, thousands of Canadian children are diagnosed with, or treated for, brain disorders such as Fetal Alcohol Spectrum Disorders (FASD), Autism Spectrum Disorders (ASD) and cerebral palsy. As a national scientific research network, NeuroDevNet has dedicated its mission towards finding the root causes of these disorders.